Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Sell
47
BHST Quote, Financials, Valuation and Earnings
Last price:
$6.3400
Seasonality move
:
-11.51%
Day range:
$6.2600 - $6.9700
52-week range:
$0.0011 - $7.3800
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.02x
P/B ratio:
81.56x
Volume:
20.4K
Avg. volume:
36.3K
1-year change:
-3.32%
Market cap:
$108.5M
Revenue:
$25.2M
EPS (TTM):
-$1.33
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, BioHarvest Sciences has 134.29% upside to fair value with a price target of $14.6667 per share.
BHST vs. S&P 500
-
Over the past 5 trading days, BioHarvest Sciences has overperformed the S&P 500 by 4.77% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioHarvest Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioHarvest Sciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioHarvest Sciences reported revenues of $6.5M.
Earnings Growth
-
BioHarvest Sciences has grown year-over-year earnings for 1 quarter straight. In the most recent quarter BioHarvest Sciences reported earnings per share of -$0.16.
Enterprise value:
110M
EV / Invested capital:
--
Price / LTM sales:
4.02x
EV / EBIT:
--
EV / Revenue:
4.37x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-11.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$12.1M
Return On Assets:
-94.11%
Net Income Margin (TTM):
-76.65%
Return On Equity:
--
Return On Invested Capital:
-331.74%
Operating Margin:
-32.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $5.5M | $12.7M | $25.2M | $4.5M | $7.3M | |
| Gross Profit | $1.2M | $5.6M | $13.9M | $2.3M | $4.1M | |
| Operating Income | -$10.6M | -$10M | -$7M | -$2.5M | -$1.7M | |
| EBITDA | -$9.1M | -$9.8M | -$5.4M | -$5.5M | -$2.5M | |
| Diluted EPS | -$0.86 | -$0.93 | -$0.85 | -$0.53 | -$0.17 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2M | $5.7M | $4.3M | $9.1M | $7.9M | |
| Total Assets | $5.3M | $10.2M | $9.4M | $15M | $25M | |
| Current Liabilities | $1.9M | $2.9M | $11.5M | $26.5M | $14.3M | |
| Total Liabilities | $7.6M | $7.4M | $15.3M | $29.9M | $23.7M | |
| Total Equity | -$2.3M | $2.9M | -$5.9M | -$14.9M | $1.3M | |
| Total Debt | -- | -- | $8.5M | $20.5M | $3.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.2M | -$8.5M | -$6.7M | -$3M | -$2.4M | |
| Cash From Investing | -$1.3M | -$1.5M | -$3M | -$291K | -$400K | |
| Cash From Financing | $8.1M | $13.6M | $6.8M | $7M | $2.5M | |
| Free Cash Flow | -$10.5M | -$10M | -$9.5M | -$3.3M | -$2.8M | |
BHST
Sector
Market Cap
$108.5M
$259.5M
Price % of 52-Week High
84.82%
73.81%
Dividend Yield
0%
0%
Shareholder Yield
--
3.16%
1-Year Price Total Return
-3.32%
-9.48%
Beta (5-Year)
1.056
0.419
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.0831
200-day SMA
Buy
Level
$5.7278
Bollinger Bands (100)
Buy
Level
5.3962 - 6.2762
Chaikin Money Flow
Sell
Level
-112.3K
20-day SMA
Buy
Level
$5.8843
Relative Strength Index (RSI14)
Buy
Level
55.6832
ADX Line
Buy
Level
17.314
Williams %R
Neutral
Level
-38.6243
50-day SMA
Buy
Level
$5.8059
MACD (12, 26)
Buy
Level
0.1165
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
387.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.0627)
Sell
CA Score
(Annual)
Level (-5.6587)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (7.7794)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Stock Forecast FAQ
In the current month, BHST has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BHST average analyst price target in the past 3 months is $14.6667.
-
Where Will BioHarvest Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioHarvest Sciences share price will rise to $14.6667 per share over the next 12 months.
-
What Do Analysts Say About BioHarvest Sciences?
Analysts are divided on their view about BioHarvest Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioHarvest Sciences is a Sell and believe this share price will drop from its current level to $12.0000.
-
What Is BioHarvest Sciences's Price Target?
The price target for BioHarvest Sciences over the next 1-year time period is forecast to be $14.6667 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BHST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioHarvest Sciences is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BHST?
You can purchase shares of BioHarvest Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioHarvest Sciences shares.
-
What Is The BioHarvest Sciences Share Price Today?
BioHarvest Sciences was last trading at $6.3400 per share. This represents the most recent stock quote for BioHarvest Sciences. Yesterday, BioHarvest Sciences closed at $6.2600 per share.
-
How To Buy BioHarvest Sciences Stock Online?
In order to purchase BioHarvest Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NextEra Energy a Stock to Hold Forever?
NextEra Energy (NYSE:NEE) share price sold off hard in recent…
Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
17
SAIA alert for Apr 29
Saia [SAIA] is down 3.49% over the past day.
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is up 17.37% over the past day.
Buy
72
SXT alert for Apr 29
Sensient Technologies [SXT] is down 0.85% over the past day.
